The effect of hormone replacement therapy on cognitive function in post-menopausal women (2007)
Lavi, R., Doniger, G.M., Simon, E., Hochner-Celnikier, D., Zimran, A., Elstein, D.
Background: Despite interest in causes of dementia in older persons, particularly in post-menopausal women, it is unclear whether hormone replacement therapy (HRT) is a risk factor. Aim: To assess...
Elstein, D., Dweck, A., Attias, D., Hadas-Halpern, I., Zevin, S., Altarescu, G., ...
Enzyme replacement therapy (ERT) with imiglucerase reduces hepatosplenomegaly and improves hematologic parameters in Gaucher disease type 1 within 6-24 months. Miglustat reduces organomegaly,...
Fibromyalgia and Gaucher's disease (2006)
Brautbar, A., Elstein, D., Pines, B., Krienen, N., Hemmer, J., Buskila, D., ...
Background: Patients with symptomatic Gaucher's disease sometimes have non-specific symptoms (such as general malaise with widespread musculoskeletal pains) that respond poorly to enzyme replacement...
Fibromyalgia and Gaucher's disease (2005)
Brautbar, A., Elstein, D., Pines, B., Krienen, N., Hemmer, J., Buskila, D., ...
Background: Patients with symptomatic Gaucher's disease sometimes have non-specific symptoms (such as general malaise with widespread musculoskeletal pains) that respond poorly to enzyme replacement...
Cox, T.M., Andria, G., Beck, M., Belmatoug, N., Bembi, B., ...
Cox, T M, Aerts, J, Andria, G, Beck, M, Belmatoug, N, Bembi, B, ...
N-Butyldeoxynojirimycin (NB-DNJ, miglustat 'Zavesca') is an orally active iminosugar which inhibits the biosynthesis of macromolecular substrates that accumulate pathologically in...
Decreased salivary output in patients with Gaucher disease (2003)
Dayan, B., Elstein, D., Zimran, A., Nesher, G.
Background: Gaucher disease, the most common sphingolipid storage disease, results in accumulation of glucocerebroside in macrophages or ‘Gaucher cells’. In a preliminary screening of 109...
The interleukin-6 promoter polymorphism in Gaucher disease: a new modifier gene? (2003)
Altarescu, G., Phillips, M., Foldes, A.J., Elstein, D., Zimran, A., Mates, M.
Background: Individuals with Gaucher disease vary significantly with regard to degree of bone disease, but there are no predictive markers for severity of skeletal involvement. Aim: To determine...
Low-dose N-butyldeoxynojirimycin (OGT 918) for type I Gaucher disease (2002)
Elstein, D, Aerts, J, Van Weely, S, Zimran, A
The objective of this study was to evaluate the efficacy and safety of low-dose substrate balance therapy with OGT 918 for the treatment of adults with Gaucher disease. Eighteen patients with Gaucher...
Hollak, C, Aerts, J, Van Weely, S, Cox, T, Lachmann, R, ...
Lung involvement and enzyme replacement therapy in Gaucher's disease (2001)
Goitein, O., Elstein, D., Abrahamov, A., Hadas-Halpern, I., Melzer, E., Kerem, E., ...
Symptomatic lung involvement in Gaucher's disease is relatively rare, being restricted to patients with other severe manifestations. We describe our experience in eight of 411 patients in our...
Lachmann, R, Hollak, C, Aerts, J, Van Weely, S, Hrebicek, M, ...
Background Current treatment for Gaucher's disease involves administration of intravenous glucocerebrosidase to degrade glucocerebroside stored in lysosomes. Lowering the rate of biosynthesis of...